SYK SYK

Name: SYK Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored March 19, 2026

Price at analysis: $330.05

Crucible Score

60.2

C+

Quality × Value Composite

KQI — Quality

70.7

Fundamental Quality Index

KVI — Value

47.4

D+

Valuation Attractiveness Index

Crucible Verdict — SYK

Stryker delivers exceptional operational execution with a perfect 22/22 earnings beat streak and strong financial quality scores, but SYK trades at a premium that leaves little margin for error given modest diversification metrics. The 12% upside to fair value provides reasonable entry opportunity for investors seeking exposure to a well-managed medical technology leader with consistent performance delivery.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

77.3

Growth Profile

75.5

Moat Durability

67.7

Management Effectiveness

67.1

Diversification & Resilience⚠

56.0

Market Position

68.0

Weakest dimension: Diversification & Resilience (56.0)

◆ KVI Value Dimensions

DCF Margin of Safety

66.5

FCF Yield & Cash Returns

30.7

Relative Valuation

38.7

Growth-Adjusted Value

30.2

Historical Valuation

72.4

Macro Context

33.0

◆ DCF Valuation Scenarios

Bear Case

$265.42

Base Case

$368.17

Bull Case

$502.89

Price at Analysis

$330.05

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$265.42	5.5%	19.0%	9.3%
🟢 Base	$368.17	7.5%	21.0%	8.7%
🟢 Bull	$502.89	9.5%	23.0%	8.2%

Key Assumptions: Revenue growth anchored to 5-year historical CAGR of ~10%, with bear assuming macro/pricing headwinds slowing growth to mid-single digits and bull reflecting robust MedTech demand and M&A synergies pushing toward high-single digits. Operating margins range from 19% (bear, reflecting recent compression from acquisitions and inflation) to 23% (bull, reflecting scale leverage and mix improvement) versus the 5-year average of ~21%. WACC derived from CAPM with 5.5% ERP for healthcare, adjusted modestly across scenarios; tax rate normalized at 16% reflecting SYK's historical effective rate excluding one-off charges.

◆ Financial Snapshot

Profitability

Gross Margin63.5%

Operating Margin22.4%

Net Margin12.9%

ROIC9.4%

ROE16.0%

Balance Sheet

Balance SheetCR: 1.89

Cash ConversionFCF/EPS: 1.32x

Capital IntensityCapex/Rev: 3.0%

Altman Z-Score4.18 (Safe)

Piotroski F-Score5/9 (Mixed)

Growth

Revenue CAGR10.1% CAGR

Earnings CAGR13.0% CAGR

Growth ConsistencyCV: 0.59

Segment Breadth2/2 growing (100%)

Quarterly TrendMargin↑, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOKevin Lobo · 14 years

CEO Ownership5.2%

Compensation91% performance-based

Insider ActivitySelling

Capital AllocationROIC 9.4% vs WACC 3.2%

Earnings Beat Rate100% (22/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted March 19, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.